Wells Fargo Downgrades Myriad Genetics (MYGN) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Jefferies Remains Sidelined on Myriad Genetics (MYGN) Following 4Q
August 11, 2016 8:37 AM EDTJefferies maintained a Hold rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $20.00 (from $34.00), following the company's 4Q earnings report. The company's weaker 4Q16 experience (-7%) and initial FY17 outlook for the HC segment (-7%) suggest pricing and... More
Mizuho Securities Cuts Price Target on Myriad Genetics (MYGN) to $22 Following 4Q and Guidance
August 10, 2016 7:19 AM EDTMizuho Securities maintained a Neutral rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $22.00 (from $34.00), following the company's 4Q results and guidance. MYGN guided to 2017 revenues of $740mm-$760mm, versus consensus of $790mm, and EPS of $1.00-$1.10, versus consensus of $1.77.... More
Piper Jaffray Downgrades Myriad Genetics (MYGN) to Neutral
August 10, 2016 6:38 AM EDTPiper Jaffray downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Neutral with a price target of $22.00 (from $47.00).
Analyst William Quirk commented, "Myriad's 4Q16 revenue declined 1.8% yoy to $186.5M, below our in line estimate of $187.7M. EPS of $0.36 was below our in line $0.37 estimate.... More
Myriad Genetics (MYGN) Misses Q4 EPS by 6c; Issues Weak Q1, FY17 Outlook
August 9, 2016 4:11 PM EDTMyriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.32, $0.06 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $186.5 million versus the consensus estimate of $187.92 million.
GUIDANCE:
Myriad Genetics sees Q1 2017 EPS of $0.25-$0.27, versus the consensus of... More
